Press Releases
Please, enter cell line, author or any other phrase or word you would like to search for.
Synthetic antibody patent awarded to PHI by Japan
PHI announces today that the Company has been granted a patent concerning synthetic antibodies in Japan.
PHI Enters Biomanufacturing Partnership with Wake Forest Institute for Regenerative Medicine
PHI and Wake Forest Institute for Regenerative Medicine recently signed a letter of intent outlining a biomanufacturing initiative to make indispensable imaging techniques available for regenerative medicine and large-scale production of cell therapies and organs.
PHI Signs Subscription Commitments with Board Members, CEO and Owners
Subscription commitments corresponding to approximately 4 % of the initial rights issue (2.9 million SEK) have been signed with members of the company’s board, the company’s CEO and with owners.
HoloMonitor Fluorescence Now at Novo Nordisk
PHI recently installed a fluorescence-equipped HoloMonitor® system at Novo Nordisk A/S. The installation is part of a series of test installations to allow experienced HoloMonitor customers to provide feedback regarding functionality and user-friendliness prior to the upcoming product launch.
PHI changes the date for publication of Interim Report 3 2021/22
The reason for the change of date is to allow management and staff to participate in the newly decided rights issue by purchasing shares.
Continued Sales Growth for PHI
PHI’s sales in November – January gained 240 % and amounted to 2.7 (0.8) MSEK. Sales over the past four fiscal quarters (Feb 2021 – Jan 2022) amount to 8.8 (2.3) MSEK.
PHI Moves to New Premises
As of today, Phase Holographic Imaging’s registered office is Skiffervägen 48, 224 78 Lund, Sweden.
The Board of Directors proposes decision on a rights issue of units and a directed issue of convertibles
The Board of Directors of Phase Holographic Imaging has today decided to propose that the Extraordinary General Meeting shall decide on a rights issue, which initially can provide the company with approx. SEK 72.4 million.
PHI Introduces Non-invasive Fluorescence
Currently, the HoloMonitor fluorescence unit is being prepared for its first users.
PHI Enters Regenerative Medicine Partnership
PHI and RegenMed Development Organization have entered a partnership to advance large-scale biomanufacturing of cell-based therapies.